---
title: "The EveryPrem Project: Evaluating the INTER-NDA for Standardized Neurodevelopmental Screening at 2 Years of Age for Children Born Preterm."
nct_id: NCT05065385
overall_status: ACTIVE_NOT_RECRUITING
sponsor: Giancarlo Natalucci
study_type: OBSERVATIONAL
primary_condition: Prematurity
countries: Switzerland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05065385.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05065385"
ct_last_update_post_date: 2026-04-14
last_seen_at: "2026-05-12T07:34:12.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The EveryPrem Project: Evaluating the INTER-NDA for Standardized Neurodevelopmental Screening at 2 Years of Age for Children Born Preterm.

**NCT ID:** [NCT05065385](https://clinicaltrials.gov/study/NCT05065385)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 800
- **Lead Sponsor:** Giancarlo Natalucci
- **Conditions:** Prematurity
- **Start Date:** 2022-03-01
- **Completion Date:** 2026-12-31
- **CT.gov Last Update:** 2026-04-14

## Brief Summary

Neurodevelopmental follow-up of infants at high-risk such as preterm born is necessary in order to early detect impairments and early start a supportive/therapeutic intervention. Valid tools should be available for screening infants with developmental problems even where resources are limited. Such screening would ensure an adequate medical care during and after hospital discharge as well as evidence-based parental pre- and postnatal counselling. While in Switzerland, these tools are specifically needed for the neurodevelopmental surveillance of moderate to late pretem born infants, in low- and mid-income countries, they are needed to monitor the whole population of preterm born infants.

To fill this important gap, the present study aims to determine whether it is feasible to extend neurodevelopmental screening (currently offered to only a very small part of children born preterm), by using a new cost-effective neurodevelopmental assessment, the INTERGROWTH-21st Neurodevelopment Assessment (INTER-NDA, www.inter-nda.com Assessment) at age 2 years.

## Detailed Description

The pirmary objectives of the study are:

1. In very preterm born infants (born \< 32 weeks' gestation)

   \- To assess the concurrent validity of the INTER-NDA with the Bayley-III\[13\] at 2 years of corrected age in VPT infants.
2. In moderate to late preterm infants (born between 32 and 36 weeks' gestation) - To screen neurodevelopment performances at corrected 2 years of corrected age in MLPT infants by means of the INTER-NDA and to compare values with international INTER-NDA standard values.

## Eligibility

- **Minimum age:** 18 Months
- **Maximum age:** 30 Months
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Former patient of the Department of Neonatology of the University Hospital Zurich
* Born between 01.01.2019 and 31.12.2021, i.e. aged 18 to 30 months at the time of the research visit
* Gestational age below 370/7 weeks
* Parent consent

Exclusion Criteria:

* Genetically defined syndrome (including chromosomal aberration) or inborn error of metabolism adversely influencing life expectancy or neurodevelopment.
* Major congenital malformations requiring surgical correction or potentially affecting neurodevelopmental outcome.
* Hypoxic ischemic encephalopathy after perinatal asphyxia defined as grade 2 or 3 according to Sarnat and Sarnat\[19\].
* Neonatal drug withdrawal syndrome or known maternal substance consumption of following illicit drugs during pregnancy: cocaine, heroin, Lysergic acid diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (ecstasy), phencyclidine (PCP), and other amphetamine/methamphetamine.
* Children of parents who are not speaking German
```

## Interventions

- **INTER-NDA** (DIAGNOSTIC_TEST) — Neurodevelopmental Screening Test at age 2 years.

## Primary Outcomes

- **INTER-NDA domain scores and centiles** _(time frame: At age 18 to 20 months; test duration 15 to 20 minutes.)_ — The INTERGROWTH-21st Neurodevelopment Assessment (INTER-NDA) is new cost-effective neurodevelopmental assessment for 2-year old infants.

## Locations (1)

- Department of Neonatology, Zurich, Canton of Zurich, Switzerland

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of neonatology|zurich|canton of zurich|switzerland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05065385.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05065385*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*